Granules India Limited

GRANULES

INE101D01020

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:48 10/05/2024 pm IST			5-day change	1st Jan Change
398 ^INR	+1.53%		-5.98%	-1.81%

30/04	Granules Pharmaceuticals Arm Gets US FDA's Approval for Generic Drug for Gout Flares	MT
15/04	Granules India Gets Zero Observation from US FDA After Inspection of Visakhapatnam, India Unit	MT

Granules India Limited Announces Cessation of Arun Rao Akinepally as Independent Director

March 29, 2024 at 07:04 pm IST

Granules India Limited informed that the second term of Mr. Arun Rao Akinepally (DIN: 00876993) as an Independent Director is completing on March 31, 2024 and he will be ceased to be the Independent Director of the Company thereafter.

Latest news about Granules India Limited

Granules Pharmaceuticals Arm Gets US FDA's Approval for Generic Drug for Gout Flares	30/04	MT
Granules India Gets Zero Observation from US FDA After Inspection of Visakhapatnam, India Unit	15/04	MT
Granules India Unit Gets VAI Status for Virginia Facility	03/04	MT
Granules India Limited Announces Appointment of Directors	02/04	CI
Granules India Limited Announces Cessation of Arun Rao Akinepally as Independent Director	29/03	CI
Granules India Limited Announces Appointment of Sethu Madhavan Sankaran as Senior Vice President - Api Manufacturing & Operations	29/03	CI
Granules India Limited Appoints Atul Dhavle as Chief Human Resources Officer	11/03	CI
Granules India Limited Announces That J. Shravan Reddy Shall Cease to Be Senior Vice President & Head- API Manufacturing	05/03	CI
Transcript : Granules India Limited, Q3 2024 Earnings Call, Jan 23, 2024	23/01
Paracetamol maker Granules India posts marginal rise in Q3 profit	23/01	RE
Granules India's Posts Gains in Fiscal Q3 Consolidated Net Profit	23/01	MT
Granules India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	23/01	CI
Granules Pharmaceuticals Unit's Virginia Facility Gets Five Observations from US FDA	18/12	MT
Granules India Gets US FDA Nod for Pantoprazole Sodium Delayed-Release Tablets	13/12	MT
Granules India Limited Receives ANDA Approval for Pantoprazole Sodium Delayed-Release Tablets	13/12	CI
Granules India Arm Gets US FDA Nod for Sildenafil for Oral Suspension	04/12	MT
Paracetamol maker Granules India's Q2 revenue rises on higher N.America demand	09/11	RE
Transcript : Granules India Limited, Q2 2024 Earnings Call, Nov 09, 2023	09/11
Granules India Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	09/11	CI
Granules India Gets US FDA's Approval for Generic Drug for GERD Symptoms	19/23/19	MT
Granules India Limited Receives ANDA Approval for Esomeprazole Magnesium Delayed-Release Capsules	19/23/19	CI
Indian paracetamol maker Valiant Laboratories lists at 16% premium	06/23/06	RE
Granules India Gets US FDA Nod for Hypertension Treatment Drug	02/23/02	MT
Granules India Limited Announces the US Food & Drug Administration Approval of its Abbreviated New Drug Application for Losartan Potassium and Hydrochlorothiazide Tablets USP	30/23/30	CI
Granules India's Telangana Facility Gets Accreditation from Japanese Regulator	25/23/25	MT

Chart Granules India Limited

Duration

Period

More charts

Company Profile

Granules India Limited is an India-based pharmaceutical manufacturing company. The Company operates through its pharmaceuticals products segment. Its geographical segments include within India and outside India. The Company has its presence across the pharmaceutical manufacturing value chain, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs) and finished dosages (FDs). It has over eight manufacturing facilities, approximately seven of which are located in India and one in the United States. The Company sells its products in the global markets, including the United States of America, Canada, Latin America, Europe, Asia Pacific and India. The Companyâs wholly owned subsidiaries include Granules USA Inc, Granules Pharmaceuticals Inc, Granules Europe Limited and Granules Lifesciences Private Limited.

Sector

Pharmaceuticals

Calendar

15/05/2024 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Granules India Limited

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

398 INR

Average target price

483.4 INR

Spread / Average Target

+21.45%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GRANULES INDIA LIMITED	-1.81%	1.15B
ELI LILLY AND COMPANY	+30.38%	684B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.36%	361B
MERCK & CO., INC.	+19.30%	329B
ABBVIE INC.	+3.73%	284B
ASTRAZENECA PLC	+16.70%	240B
NOVARTIS AG	+8.78%	208B
ROCHE HOLDING AG	-7.93%	200B
AMGEN INC.	+7.68%	166B

Other Pharmaceuticals